Placebo-Controlled Evaluation of Four Novel Compounds for the Treatment of Schizophrenia and Schizoaffective Disorder

OBJECTIVE: Four studies using identical protocols evaluated the safety and efficacy of four novel, evidence-based targets for antipsychotic agents: a neurokinin (NK3) antagonist (SR142801), a serotonin 2A 2C (5-HT2A 2C) antagonist (SR46349B), a central cannabinoid (CB1) antagonist (SR141716), and a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of psychiatry 2004-06, Vol.161 (6), p.975-984
Hauptverfasser:	Meltzer, Herbert Y., Arvanitis, Lisa, Bauer, Deborah, Rein, Werner
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antipsychotic Agents - pharmacology Antipsychotic Agents - therapeutic use Biological and medical sciences Cannabinoids - antagonists & inhibitors Clinical trials Double-Blind Method Drug therapy Drugs, Investigational - therapeutic use Female Haloperidol - therapeutic use Humans Male Medical sciences Medical treatment Middle Aged Neuropharmacology Neurotensin - antagonists & inhibitors Peptide Fragments - antagonists & inhibitors Pharmacology. Drug treatments Piperidines - therapeutic use Placebos Psychiatry Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Psychotic Disorders - drug therapy Pyrazoles - therapeutic use Pyrrolidonecarboxylic Acid - analogs & derivatives Receptors, Neurokinin-3 - antagonists & inhibitors Research Design Schizophrenia Schizophrenia - drug therapy Serotonin 5-HT2 Receptor Antagonists Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!